Fmr LLC Raises Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Fmr LLC raised its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 24.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 98,580 shares of the biopharmaceutical company’s stock after purchasing an additional 19,270 shares during the quarter. Fmr LLC owned 0.08% of Catalyst Pharmaceuticals worth $1,960,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Pacer Advisors Inc. raised its position in shares of Catalyst Pharmaceuticals by 130,918.8% during the second quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after buying an additional 2,965,310 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Catalyst Pharmaceuticals by 15.2% during the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock valued at $33,702,000 after buying an additional 287,300 shares during the last quarter. Integral Health Asset Management LLC bought a new stake in shares of Catalyst Pharmaceuticals during the second quarter valued at approximately $4,260,000. Dimensional Fund Advisors LP raised its position in shares of Catalyst Pharmaceuticals by 9.6% during the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company’s stock valued at $46,479,000 after buying an additional 263,099 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Catalyst Pharmaceuticals by 87.1% during the second quarter. AQR Capital Management LLC now owns 488,386 shares of the biopharmaceutical company’s stock valued at $7,565,000 after buying an additional 227,321 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on CPRX. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Truist Financial lifted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Finally, Stephens started coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $31.14.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 12,000 shares of the business’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.72, for a total transaction of $272,640.00. Following the transaction, the insider now owns 51,391 shares in the company, valued at $1,167,603.52. The trade was a 18.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the transaction, the insider now owns 686,996 shares in the company, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock worth $1,754,140 over the last quarter. Insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX opened at $21.38 on Monday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $13.12 and a fifty-two week high of $24.27. The stock has a market capitalization of $2.55 billion, a PE ratio of 18.12, a P/E/G ratio of 3.35 and a beta of 0.75. The company’s fifty day moving average is $21.62 and its 200 day moving average is $19.18.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.